Unicycive Therapeutics, Inc.

NASDAQ:UNCY

Biotechnology

Healthcare
$3.57 -3.40%

-$0.24 today

Market cap
$104.19M
Beta
1.73
P/E (TTM)
-40.8
EPS (TTM)
-$0.17
52W Low $3.71High $8.74

Volume 1.39M

Average 0.65M

UNCY EBITDA Margin

EBITDA as a percentage of revenue.

Unicycive Therapeutics, Inc.NASDAQ: UNCY

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin not reported for Q1 FY2026

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
—— QoQ
Last fiscal yearDec 2025
—— YoY
LTMMar 2026
—— YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2023
-4470.8%
Year-over-year change
-2589.5pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How UNCY compares with its peers on the latest reported figures

UNCY Competitors Peer median
EBITDA Margin for UNCY and competitors
Company Period LTM level YoY 3-year change
VXRTVaxart, Inc.LTM Mar 202618.5% +115.0 pp+94012.8 pp
HYFTMindWalk Holdings Corp.LTM Jan 2026-59.3% +202.1 pp-55.7 pp
CAMPCAMP4 Therapeutics CorporationLTM Mar 2026-1327.8% +2091.5 pp—
CBUSCibus, Inc.LTM Mar 2026-1453.8% +4107.2 pp+7193.6 pp
UNCYUnicycive Therapeutics, Inc.FY2025— ——
RLMDRelmada Therapeutics, Inc.FY2025— ——
IMUXImmunic, Inc.FY2025— ——
PMVPPMV Pharmaceuticals, Inc.FY2025— ——
ACRVAcrivon Therapeutics, Inc. Common StockFY2025— ——
BMEABiomea Fusion, Inc.FY2025— ——
Peer median (excluding UNCY) -693.5%+1146.8 pp+7193.6 pp

Competitors are the stored peer set for UNCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0951K675K00
Cost of Revenue0000572K
Gross Profit0951K675K0(572K)
Gross Margin—100.0%100.0%——
Research & Development6.08M12.44M12.9M20.01M9.12M
Selling, General & Admin2.9M6.57M8.55M12.1M20.4M
Operating Expenses8.98M19M21.45M32.12M28.95M
Depreciation & Amortization13K161K284K428K572K
EBITDA(9.38M)(17.89M)(30.18M)(36.23M)(25.91M)
EBITDA Margin—-1881.3%-4470.8%——
Operating Income(8.98M)(18.05M)(20.77M)(32.12M)(29.52M)
Operating Margin—-1898.2%-3077.6%——
Interest Income00615K1.26M1.01M
Interest Expense628K6K82K71K71K
Other Income / Expenses(1.04M)(6K)(9.77M)(4.61M)2.96M
Income Before Tax(10.02M)(18.06M)(30.54M)(36.73M)(26.56M)
Pre-Tax Margin—-1898.8%-4525.0%——
Income Tax Expense00000
Net Income(10.02M)(18.06M)(30.54M)(36.73M)(26.56M)
Net Margin—-1898.8%-4525.0%——
EPS (Basic)(8.60)(1.20)(1.28)(5.60)(1.67)
EPS (Diluted)(8.60)(1.20)(1.28)(5.60)(1.67)
Weighted Avg Shares1.17M1.51M2.45M6.7M158.87M
Weighted Avg Shares (Diluted)1.17M1.51M2.45M6.7M158.87M

Unicycive Therapeutics, Inc.

NASDAQ:UNCY

Intrinsic Alpha fair value

Locked

Current Price

$3.57

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.